Cancer News
OncoLink Cancer News - HealthDay


Synribo Approved to Treat Chronic Myelogenous Leukemia

Friday, October 26, 2012 (Last Updated: 10/29/2012)

FRIDAY, Oct. 26 (HealthDay News) -- Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat chronic myelogenous leukemia (CML).

Some 5,430 people will be diagnosed with CML this year, the U.S. National Institutes of Health estimates. Synribo has been sanctioned to treat cases in which two other specific anti-cancer drugs have failed to stop CML's progression, the FDA said Friday in a news release.

Synribo is designed to be injected twice daily in different regimens for a number of consecutive days until white blood cell counts normalize, the agency said.

The most common adverse reactions observed during clinical testing included anemia, a drop in white blood cells, nausea, weakness, fatigue, and injection-site reaction.

Synribo is marketed by the Israeli drug maker Teva Pharmaceuticals, with U.S. headquarters in Frazer, Pa.

More information

The U.S. National Library of Medicine has more about CML.

Specialties Hematology & Oncology
OBGYN & Women's Health
Nursing

Copyright © 2012 HealthDay. All rights reserved.


I Wish You Knew

About life with cancer

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More